ORIGINAL ARTICLE Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis Kai-Xiong Liu1,2*, Bing Xu3*, Jie Wang4, Jing Zhang5, Hai-Bo Ding1,2, Felinda Ariani4, Jie-Ming Qu4, Qi-Chang Lin1,2 1
Department of Respiratory disease, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; 2Laboratory of Respiratory Disease of Fujian Medical University, Fuzhou 350005, China; 3Department of Neurology, Fujian Geriatric Hospital, Fuzhou 350003, China; 4Department of Respiratory Medicine, Huadong Hospital, Shanghai Medical School of Fudan University, Shanghai 200040, China; 5Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai Medical School of Fudan University, Shanghai 200032, China
ABSTRACT
KEYWORDS
Purpose: To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD). Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted data and reviewed the quality of the studies independently. The primary outcome was clinical success at early follow-up. Study-level data were pooled using a random-effects model when I2 was >50% or a fixed-effects model when I2 was
Department of Respiratory disease, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China; 2Laboratory of Respiratory Disease of Fujian Medical University, Fuzhou 350005, China; 3Department of Neurology, Fujian Geriatric Hospital, Fuzhou 350003, China; 4Department of Respiratory Medicine, Huadong Hospital, Shanghai Medical School of Fudan University, Shanghai 200040, China; 5Department of Pulmonary Medicine, Zhongshan Hospital, Shanghai Medical School of Fudan University, Shanghai 200032, China
ABSTRACT
KEYWORDS
Purpose: To evaluate the efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (AECOPD). Methods: We searched PubMed, EMBASE, and the Web of Science for relevant studies. Two reviewers extracted data and reviewed the quality of the studies independently. The primary outcome was clinical success at early follow-up. Study-level data were pooled using a random-effects model when I2 was >50% or a fixed-effects model when I2 was
